Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC-8
2021-004327-32Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2022
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab + domvanalimab with Durvalumab + placebo (2 arms). Primary endpoint: Progression-free survival in participants with PD-L1 TC >= 50%. Started Jan 2022; status: active.
02
Drugs
durvalumabdomvanalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2021-004327-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004327-32.